Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Takeda Pharmaceutical Company Limited Stories

2014-04-08 00:22:26

DEERFIELD, Ill., April 8, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 the jury found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly. The trial began...

2014-03-31 16:26:29

EMERYVILLE, Calif. and OSAKA, Japan, March 31, 2014 /PRNewswire/ -- Trianni, Inc. ("Trianni") and Takeda Pharmaceutical Company Limited ("Takeda") jointly announced today that they have entered into a license agreement for Takeda's use of the Trianni Mouse, a monoclonal antibody discovery platform. Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the...

2014-03-27 08:34:15

Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome WASHINGTON and OSAKA, Japan, March 27, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome)...

2014-02-20 12:27:47

Takeda will advance the CEOi's goal of building global momentum behind the G8's 2025 commitments WASHINGTON, Feb. 20, 2014 /PRNewswire-USNewswire/ -- The Global CEO Initiative (CEOi) on Alzheimer's Disease today announced that Takeda Pharmaceutical Company Limited ("Takeda") will join the CEOi as part of its effort to spur innovations in research and accelerate a means of prevention for Alzheimer's and Dementia, building momentum behind the G8's commitment to stop the disease by...

2014-01-07 08:31:26

PUNE, India, January 7, 2014 /PRNewswire/ -- Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Company, announced today that it has received the first year milestone in its Research and Development Collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone underscores the success of the collaboration and also provides validation of Advinus' capabilities in innovative Drug Discovery and Takeda's confidence in these...

2013-12-24 12:21:43

Crohn's disease action date remains unchanged DEERFIELD, Ill. and OSAKA, Japan, Dec. 24, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food & Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Priority Review action date for the ulcerative colitis (UC) indication of Takeda's investigational biologic,...

2013-12-09 20:23:04

Takeda announces positive vote on vedolizumab to treat ulcerative colitis and Crohn's disease DEERFIELD, Ill. and OSAKA, Japan, Dec. 9, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States (U.S.) Food and Drug Administration (FDA) voted to...

2013-11-14 12:26:55

Company's Outstanding Benefits, Work/Life Balance and Rewarding Career Opportunities Support Ranking DEERFIELD, Ill., Nov. 14, 2013 /PRNewswire/ -- Takeda Pharmaceuticals announced today that the Chicago Tribune named Takeda's Deerfield campus among Chicago's Top 100 Workplaces in 2013. The Chicago Tribune's Top Workplaces list is determined by anonymous feedback from employees of participating companies who credited their employers with having dynamic, supportive and inclusive cultures. "To...

2013-11-05 23:28:06

This grant awarded to Northwest Natural Health Specialty Care Clinic marks the first time a global pharmaceutical company has contracted with an independent naturopathic clinic to investigate a natural medicine combination--with a state-of-the-art cancer drug--for relief of cancer treatment side effects. Seattle, WA (PRWEB) November 05, 2013 Northwest Natural Health Specialty Care Clinic (NNH) announced today it has been awarded a $560,000 research grant by Millennium: The Takeda Oncology...

2013-10-01 00:21:41

OSAKA, Japan and COPENHAGEN, Denmark, Sept. 30, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million adult Americans in a given year.(1 )The mechanism of the antidepressant effect of Brintellix...